Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Alberta Cancer Board |
---|---|
Information provided by: | Alberta Cancer Board |
ClinicalTrials.gov Identifier: | NCT00414570 |
The objective of this pilot study are (i) to compare response to chemotherapy, time to disease progression and overall survival in patients with pancreatic cancer who will be treated with gemcitabine who demonstrate 18F-FLT uptake to those patients who do not demonstrate 18F-FLT uptake; (ii) to correlate 18F-FLT uptake with hENT1 expression with biopsy samples where available; (iii)to determine the presence or absence of uptake, the relative uptake score (RUS) and tumor to background ratios of 18F-FLT in patients with known carcinoma of the pancreas and assess this uptake in relation to time to disease progression; and (iv) to demonstrate the safety of 18F-FLT manufactured at the Edmonton PET Centre.
Condition | Intervention |
---|---|
Pancreatic Cancer |
Procedure: Positron-Emission Tomography (PET) 18F-FLT |
Study Type: | Interventional |
Study Design: | Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
Official Title: | An Imaging Pilot Study of 18F-Fluoro-3'-Deoxy-3'-L-Fluorothymidine (18F-FLT) in Patients With Locally Advanced or Metastatic Pancreatic Cancer Who Will be Treated With Gemcitabine |
Estimated Enrollment: | 30 |
Study Start Date: | November 2006 |
Estimated Study Completion Date: | November 2012 |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Sandy McEwan, MD | 780-432-8524 | sandymce@cancerboard.ab.ca |
Canada, Alberta | |
Cross Cancer Institute | Recruiting |
Edmonton, Alberta, Canada, T6G 1X2 | |
Contact: Clinical Research Unit 780-989-8152 clinical_trials_cci@cancerboard.ab.ca | |
Principal Investigator: Sandy McEwan, MD |
Principal Investigator: | Sandy McEwan, MD | Alberta Cancer Board |
Study ID Numbers: | SP-14-0054 |
Study First Received: | December 19, 2006 |
Last Updated: | September 22, 2008 |
ClinicalTrials.gov Identifier: | NCT00414570 |
Health Authority: | Canada: Health Canada |
Positron Emission Tomography (PET) 3'-deoxy-3'(18F)fluorothymidine ([18F]FLT) |
Digestive System Diseases Digestive System Neoplasms Pancreatic Neoplasms Endocrine System Diseases Pancreatic Diseases |
Gastrointestinal Neoplasms Endocrinopathy Gemcitabine Endocrine Gland Neoplasms |
Antimetabolites Anti-Infective Agents Antimetabolites, Antineoplastic Molecular Mechanisms of Pharmacological Action Immunologic Factors Antineoplastic Agents Physiological Effects of Drugs Enzyme Inhibitors |
Antiviral Agents Immunosuppressive Agents Pharmacologic Actions Neoplasms Neoplasms by Site Radiation-Sensitizing Agents Therapeutic Uses |